vs

Side-by-side financial comparison of COGNEX CORP (CGNX) and Doximity, Inc. (DOCS). Click either name above to swap in a different company.

COGNEX CORP is the larger business by last-quarter revenue ($252.3M vs $185.1M, roughly 1.4× Doximity, Inc.). Doximity, Inc. runs the higher net margin — 33.3% vs 12.9%, a 20.3% gap on every dollar of revenue. On growth, COGNEX CORP posted the faster year-over-year revenue change (9.9% vs 9.8%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs 9.4%).

Cognex Corporation is an American manufacturer of machine vision systems, software and sensors. Cognex is headquartered in Natick, Massachusetts, USA with offices in more than 20 countries.

Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.

CGNX vs DOCS — Head-to-Head

Bigger by revenue
CGNX
CGNX
1.4× larger
CGNX
$252.3M
$185.1M
DOCS
Growing faster (revenue YoY)
CGNX
CGNX
+0.1% gap
CGNX
9.9%
9.8%
DOCS
Higher net margin
DOCS
DOCS
20.3% more per $
DOCS
33.3%
12.9%
CGNX
Faster 2-yr revenue CAGR
DOCS
DOCS
Annualised
DOCS
25.2%
9.4%
CGNX

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
CGNX
CGNX
DOCS
DOCS
Revenue
$252.3M
$185.1M
Net Profit
$32.7M
$61.6M
Gross Margin
65.7%
89.9%
Operating Margin
14.0%
38.9%
Net Margin
12.9%
33.3%
Revenue YoY
9.9%
9.8%
Net Profit YoY
15.2%
-18.1%
EPS (diluted)
$0.20
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CGNX
CGNX
DOCS
DOCS
Q4 25
$252.3M
$185.1M
Q3 25
$276.9M
$168.5M
Q2 25
$249.1M
$145.9M
Q1 25
$216.0M
$138.3M
Q4 24
$229.7M
$168.6M
Q3 24
$234.7M
$136.8M
Q2 24
$239.3M
$126.7M
Q1 24
$210.8M
$118.1M
Net Profit
CGNX
CGNX
DOCS
DOCS
Q4 25
$32.7M
$61.6M
Q3 25
$17.7M
$62.1M
Q2 25
$40.5M
$53.3M
Q1 25
$23.6M
$62.5M
Q4 24
$28.3M
$75.2M
Q3 24
$29.6M
$44.2M
Q2 24
$36.2M
$41.4M
Q1 24
$12.0M
$40.6M
Gross Margin
CGNX
CGNX
DOCS
DOCS
Q4 25
65.7%
89.9%
Q3 25
67.6%
90.3%
Q2 25
67.4%
89.2%
Q1 25
66.8%
89.5%
Q4 24
68.7%
91.6%
Q3 24
67.9%
90.0%
Q2 24
69.6%
89.3%
Q1 24
67.3%
89.4%
Operating Margin
CGNX
CGNX
DOCS
DOCS
Q4 25
14.0%
38.9%
Q3 25
20.9%
37.8%
Q2 25
17.4%
37.4%
Q1 25
12.1%
35.2%
Q4 24
13.4%
47.4%
Q3 24
13.4%
38.8%
Q2 24
16.1%
36.4%
Q1 24
6.7%
35.5%
Net Margin
CGNX
CGNX
DOCS
DOCS
Q4 25
12.9%
33.3%
Q3 25
6.4%
36.8%
Q2 25
16.3%
36.5%
Q1 25
10.9%
45.2%
Q4 24
12.3%
44.6%
Q3 24
12.6%
32.3%
Q2 24
15.1%
32.7%
Q1 24
5.7%
34.4%
EPS (diluted)
CGNX
CGNX
DOCS
DOCS
Q4 25
$0.20
$0.31
Q3 25
$0.10
$0.31
Q2 25
$0.24
$0.27
Q1 25
$0.14
$0.31
Q4 24
$0.17
$0.37
Q3 24
$0.17
$0.22
Q2 24
$0.21
$0.21
Q1 24
$0.07
$0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CGNX
CGNX
DOCS
DOCS
Cash + ST InvestmentsLiquidity on hand
$262.9M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.5B
$979.3M
Total Assets
$2.0B
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CGNX
CGNX
DOCS
DOCS
Q4 25
$262.9M
$64.8M
Q3 25
$245.9M
$169.2M
Q2 25
$179.3M
$137.3M
Q1 25
$143.7M
$209.6M
Q4 24
$186.1M
$165.3M
Q3 24
$197.1M
$184.2M
Q2 24
$176.6M
$111.4M
Q1 24
$138.9M
$96.8M
Stockholders' Equity
CGNX
CGNX
DOCS
DOCS
Q4 25
$1.5B
$979.3M
Q3 25
$1.5B
$1.1B
Q2 25
$1.5B
$1.0B
Q1 25
$1.4B
$1.1B
Q4 24
$1.5B
$1.0B
Q3 24
$1.6B
$961.2M
Q2 24
$1.5B
$913.6M
Q1 24
$1.5B
$901.4M
Total Assets
CGNX
CGNX
DOCS
DOCS
Q4 25
$2.0B
$1.2B
Q3 25
$2.0B
$1.3B
Q2 25
$2.0B
$1.2B
Q1 25
$1.9B
$1.3B
Q4 24
$2.0B
$1.2B
Q3 24
$2.1B
$1.1B
Q2 24
$2.0B
$1.1B
Q1 24
$2.0B
$1.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CGNX
CGNX
DOCS
DOCS
Operating Cash FlowLast quarter
$74.9M
$60.9M
Free Cash FlowOCF − Capex
$72.3M
FCF MarginFCF / Revenue
28.7%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
2.29×
0.99×
TTM Free Cash FlowTrailing 4 quarters
$236.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CGNX
CGNX
DOCS
DOCS
Q4 25
$74.9M
$60.9M
Q3 25
$87.5M
$93.9M
Q2 25
$42.6M
$62.1M
Q1 25
$40.5M
$98.5M
Q4 24
$51.4M
$65.2M
Q3 24
$56.3M
$68.3M
Q2 24
$27.8M
$41.2M
Q1 24
$13.6M
$63.9M
Free Cash Flow
CGNX
CGNX
DOCS
DOCS
Q4 25
$72.3M
Q3 25
$86.0M
Q2 25
$40.4M
Q1 25
$38.0M
Q4 24
$49.3M
Q3 24
$51.9M
Q2 24
$23.3M
Q1 24
$9.6M
FCF Margin
CGNX
CGNX
DOCS
DOCS
Q4 25
28.7%
Q3 25
31.1%
Q2 25
16.2%
Q1 25
17.6%
Q4 24
21.5%
Q3 24
22.1%
Q2 24
9.7%
Q1 24
4.5%
Capex Intensity
CGNX
CGNX
DOCS
DOCS
Q4 25
1.0%
Q3 25
0.5%
Q2 25
0.9%
Q1 25
1.2%
0.0%
Q4 24
0.9%
0.0%
Q3 24
1.9%
0.0%
Q2 24
1.9%
0.0%
Q1 24
1.9%
0.0%
Cash Conversion
CGNX
CGNX
DOCS
DOCS
Q4 25
2.29×
0.99×
Q3 25
4.95×
1.51×
Q2 25
1.05×
1.16×
Q1 25
1.72×
1.58×
Q4 24
1.81×
0.87×
Q3 24
1.90×
1.55×
Q2 24
0.77×
1.00×
Q1 24
1.13×
1.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CGNX
CGNX

Segment breakdown not available.

DOCS
DOCS

Subscription$175.4M95%
Service Other$9.7M5%

Related Comparisons